HIV-1 protease inhibitor–associated partial lipodystrophy: Clinicopathologic review of 14 cases - 05/09/11
Abstract |
Background: A novel type of acquired partial lipodystrophy resulting from chronic treatment with HIV-1 protease inhibitor drugs has recently been described. Objective: We studied the clinical and histopathologic features of a series of patients with HIV-1 protease inhibitor–associated lipodystrophy to evaluate the frequency of associated abnormalities. Methods: The study group consisted of 14 consecutive HIV-infected patients receiving treatment with HIV-1 protease inhibitors, who experienced partial lipodystrophy. Clinical (including anthropometric data) and histopathologic findings, as well as biochemical and virologic data, were evaluated. Results: A significant loss of fat in the face and extremities was associated with fat deposition on the abdomen, breast, and dorsocervical fat pad. Central obesity was frequently present. Histopathologic features disclosed a peculiar type of involutional lipodystrophy. Hypertriglyceridemia was detected in 78.5% of patients. Low serum levels of cholesterol–high-density lipoprotein and high cholesterol–very-low-density lipoprotein were noted. Hyperglycemia, hypercholesterolemia, or hyperinsulinemia were occasionally detected. Conclusion: HIV-1 protease inhibitor–associated lipodystrophy represents a new entity with peculiar clinical and histopathologic features. Metabolic associated abnormalities may imply a risk of future atherogenic complications. (J Am Acad Dermatol 2000;42:193-8.)
Le texte complet de cet article est disponible en PDF.Plan
Reprint requests: Ramon M. Pujol, MD, Department of Dermatology, Hospital de la Santa Creu i Sant Pau, Avda Sant Antoni M Claret 167, 08025-Barcelona, Spain. |
|
0190-9622/2000/$12.00 + 0 16/1/100948 |
Vol 42 - N° 2P1
P. 193-198 - février 2000 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?